MedTrace Logo

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

NCT01413568 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2016-02-26

No results posted yet for this study

Summary

Determine the safety and tolerability of POL6326 when used as a single mobilization agent.

Conditions

  • Acute Myeloid Leukemia in Remission
  • Adult Acute Lymphoblastic Leukemia in Remission
  • Chronic Myelogenous Leukemia (CML)
  • Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma (MM)
  • Myelodysplastic Syndrome (MDS)
  • Myeloproliferative Disorders

Interventions

DRUG

POL6326

PROCEDURE

Leukapheresis

PROCEDURE

PBSC Transplant

Sponsors & Collaborators

  • Polyphor Ltd.

    lead INDUSTRY

Principal Investigators

  • Daniel Couriel, M.D. · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-11-30
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01413568 on ClinicalTrials.gov